EcoDrugPlus

Proteasome 20s Subunit Alpha 5

Ensembl ID : ENSSVLG00005012503
Gene Symbol: PSMA5
1 Cross references
209 Possible Orthologues:

Proteasome 20s Subunit Alpha 6

Ensembl ID : ENSSVLG00005002482
Gene Symbol: PSMA6
1 Cross references
252 Possible Orthologues:

Proteasome 20s Subunit Alpha 8

Ensembl ID : ENSSVLG00005010327
Gene Symbol: PSMA8
1 Cross references
197 Possible Orthologues:

Proteasome 20s Subunit Beta 10

Ensembl ID : ENSSVLG00005021819
Gene Symbol: PSMB10
1 Cross references
171 Possible Orthologues:

Proteasome 20s Subunit Beta 2

Ensembl ID : ENSSVLG00005001408
Gene Symbol: PSMB2
1 Cross references
219 Possible Orthologues:

Proteasome 20s Subunit Beta 3

Ensembl ID : ENSSVLG00005015772
Gene Symbol: PSMB3
1 Cross references
234 Possible Orthologues:

Proteasome 20s Subunit Beta 4

Ensembl ID : ENSSVLG00005002561
Gene Symbol: PSMB4
1 Cross references
213 Possible Orthologues:

Proteasome 20s Subunit Beta 6

Ensembl ID : ENSSVLG00005011168
Gene Symbol: PSMB6
1 Cross references
210 Possible Orthologues:

Proteasome 20s Subunit Beta 7

Ensembl ID : ENSSVLG00005021459
Gene Symbol: PSMB7
1 Cross references
218 Possible Orthologues:

Proteasome 20s Subunit Beta 8

Ensembl ID : ENSSVLG00005006647
Gene Symbol: PSMB8
1 Cross references
220 Possible Orthologues:

Proteasome 20s Subunit Beta 9

Ensembl ID : ENSSVLG00005006563
Gene Symbol: PSMB9
1 Cross references
212 Possible Orthologues:

Proteasome 26s Subunit Ubiquitin Receptor, Non-Atpase 2

Ensembl ID : ENSSVLG00005013466
Gene Symbol: PSMD2
1 Cross references
222 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).